RedHill Biopharma (RDHL) announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market that the Company has regained compliance with the stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Expands Offering of American Depositary Shares
- RedHill says $10.5M New York Supreme Court judgment now final for enforcement
- RedHill Biopharma Secures $10.5 Million Judgment Win
- RedHill Biopharma announces $10.5M New York Supreme Court judgment win
- RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost